C4 Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held by C4 Therapeutics, Inc. on June 24, 2026. The filing details the voting results for four specific proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders voted on the following matters at the Annual Meeting:
- Election of Directors: Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar were elected as Class III directors to serve until the 2029 annual meeting. All three candidates received majority support.
- Executive Compensation: A non-binding advisory vote to approve named executive officer compensation passed with 54,935,574 votes "For" versus 1,070,926 "Against."
- Auditor Ratification: Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 76,891,210 votes "For."
- Stock Plan Amendment: Stockholders approved an amendment to the 2020 Stock Option and Incentive Plan. The amendment modifies the evergreen provision to include outstanding pre-funded warrants in the calculation of shares issued and outstanding as of each December 31.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies beyond the standard disclosure of the voting results and the amendment to the stock plan.
Key Facts for Investor Verification
- Verify the impact of the approved amendment to the 2020 Stock Option and Incentive Plan on future share dilution, specifically regarding the inclusion of pre-funded warrants in the evergreen calculation.
- Confirm the composition of the Board of Directors following the election of the new Class III directors.
- Review the definitive proxy statement filed on April 29, 2026, for detailed context on the executive compensation proposal and the rationale for the stock plan amendment.